Reveals that CCDC80 reduces migration in high-grade serous ovarian cancer, suggesting it as a potential therapeutic target.
Paired box protein Pax-8 (PAX8) is a critical lineage marker and master regulator of transcription in high-grade serous ovarian carcinoma (HGSC)-the most common subtype of epithelial ovarian cancer-driving cell proliferation and migration and resisting apoptosis. This study aimed to elucidate the mechanism of action of PAX8 in this disease. By performing an unbiased analysis of PAX8-regulated genes, we discovered two PAX8-regulated genes-coiled-coil domain-containing protein 80 (CCDC80) and cluster of differentiation 276 (CD276) antigen (also known as B7-H3)-that mediate PAX8 activity and play key cancer cell autonomous roles in this disease. Our findings indicate that PAX8 negatively regulates CCDC80, a novel cell autonomous tumor suppressor in HGSC. We demonstrate that CCDC80, localized to the nucleus, significantly reduces HGSC tumor growth and metastasis in vivo in a mouse model. Notably, CCDC80 exerts its function by suppressing the expression of the immune checkpoint protein B7-H3. However, in HGSC, B7-H3 is predominantly cytoplasmic and promotes HGSC proliferation and migration independent of its immune role. Additionally, PAX8 positively regulates B7-H3 expression in a CCDC80-independent manner, underscoring the multifaceted oncogenic role of PAX8. This study highlights the complex regulatory network involving PAX8, CCDC80, and B7-H3 in HGSC progression. Targeting this signaling pathway may provide a novel therapeutic strategy to improve treatment outcomes for patients with epithelial ovarian cancer. B7-H3, which is currently targeted in clinical trials, shows promise as HGSC target for therapy.
No takes yet. Share an insight, caveat, or question.
Saleh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: